Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System<sup>™</sup>

Movérare, Robert; Elfman, Lena; Vesterinen, Erkki; Metso, T.; Haahtela, Tari

doi:10.1034/j.1398-9995.2002.13248.x

Cited by 139 publications

(111 citation statements)

References 44 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…Another possibility is that important allergens are either not present in the allergen extracts in sufficient amounts or they exhibit poor immunogenicity [21,31]. Furthermore, it has been reported that administration of natural allergen extracts can induce new IgE specificities against allergens present in the extracts, which were not recognized by the patient before treatment [45][46][47].…”

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

“…1, left, lower image), which will activate allergen-specific T cells to proliferate and release pro-inflammatory cytokines. Second, administration of allergens may induce allergen-specific IgE antibody production either by boosting of already existing B epsilon cells or by inducing de novo an allergenspecific IgE response [45][46][47]. The more the administered allergen resembles the structure of the natural allergen the more it will be able to boost already existing IgE responses and to exhibit sensitizing capacity.…”

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

See 1 more Smart Citation

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

100

View full text Add to dashboard Cite

SummaryAllergen-specific immunotherapy (SIT) is the only specific and disease-modifying approach for the treatment of allergy but several disadvantages have limited its broad applicability. We argue that the majority of the possible disadvantages of SIT such as unwanted effects, poor efficacy and specificity as well as inconvenient application are related to the poor quality of natural allergen extracts, which are the active ingredients of all currently available allergy vaccines. Because of the progress made in the field of molecular allergen characterization, new allergy vaccines based on recombinant allergens, recombinant hypoallergenic allergen derivatives and allergen-derived T cell peptides have entered clinical testing and hold promise to reduce the side-effects and to increase the specificity as well as the efficacy of SIT. Here, we present a refined immunotherapy concept, which is based on the use of peptides derived from allergen surfaces that exhibit reduced, allergen-specific IgE as well as T cell reactivity. These peptides when fused to non-allergenic carriers give rise to allergen-specific protective IgG responses with T cell help from a non-allergenic carrier molecule. We summarize the experimental data demonstrating that such peptide vaccines can bypass allergen-specific IgE as well as T cell activation and may be administered at high doses without IgE-and T cell-mediated side-effects. Should these peptide vaccines prove efficacious and safe in clinical trials, it may become possible to develop convenient, safe and broadly applicable forms of SIT as true alternatives to symptomatic, drug-based allergy treatment.

show abstract

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

100

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7] In our study only 5 patients had been treated with SIT more than 10 years before the first serum sample was obtained. We can therefore exclude SIT-induced effects on IgE reactivity profiles in our patients.…”

mentioning

confidence: 99%

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults

Lupinek

Marth

Niederberger

et al. 2012

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Induction of IgE sensitization against native allergens instead of development of a protective immune response might be a major problem with current allergen extractbased vaccines [13]. In addition, some individuals might already be sensitized against some of the allergens in the vaccine content.…”

Section: Discussionmentioning

confidence: 99%

Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes

Karamloo¹,

Schmid‐Grendelmeier

Kussebi³

et al. 2005

Eur. J. Immunol.

View full text Add to dashboard Cite

Novel approaches for the prevention of allergy are required, because of the inevitably increasing prevalence of allergic diseases during the last 30 years. Here, a recombinant chimeric protein, which comprises the whole amino acid sequences of three bee venom major allergens has been engineered and used in prevention of bee venom sensitization in mice. Phospholipase A 2 (Api m 1), hyaluronidase (Api m 2) and melittin (Api m 3) fragments with overlapping amino acids were assembled in a different order in the Api m (1/2/3) chimeric protein, which preserved entire T cell epitopes, whereas B cell epitopes of all three allergens were abrogated. Accordingly, IgE cross-linking leading to mast cell and basophil mediator release was profoundly reduced in humans. Supporting these findings, the Api m (1/2/3) induced 100 to 1000 times less type-1 skin test reactivity in allergic patients. Treatment of mice with Api m (1/2/3) led to a significant reduction of specific IgE development towards native allergen, representing a protective vaccine effect in vivo. These results demonstrate a novel prototype of a preventive allergy vaccine, which preserves the entire T cell epitope repertoire, but bypasses induction of IgE against native allergen, and side effects related to mast cell/basophil IgE FceRI cross-linking in sensitized individuals.

show abstract

Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System^™

Abstract: Sensitization to additional allergenic pollen components frequently occurs during prolonged birch RIT. However, the IgE levels are low and the clinical relevance is not known.

Cited by 139 publications

References 44 publications

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults

Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes

Contact Info

Product

Resources

About

Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System™

Abstract: Sensitization to additional allergenic pollen components frequently occurs during prolonged birch RIT. However, the IgE levels are low and the clinical relevance is not known.

Cited by 139 publications

References 44 publications

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults

Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes

Contact Info

Product

Resources

About

Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System^™